Search Results - "Heubner, Martin L"

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial by Pfisterer, Jacobus, Joly, Florence, Kristensen, Gunnar, Rau, Joern, Mahner, Sven, Pautier, Patricia, El-Balat, Ahmed, Kurtz, Jean-Emmanuel, Canzler, Ulrich, Sehouli, Jalid, Heubner, Martin L, Hartkopf, Andreas D, Baumann, Klaus, Hasenburg, Annette, Hanker, Lars C, Belau, Antje, Schmalfeldt, Barbara, Denschlag, Dominik, Park-Simon, Tjoung-Won, Selle, Frédéric, Jackisch, Christian, Burges, Alexander, Lück, Hans-Joachim, Emons, Günter, Meier, Werner, Gropp-Meier, Martina, Schröder, Willibald, de Gregorio, Nikolaus, Hilpert, Felix, Harter, Philipp

“…To compare standard versus extended duration of bevacizumab treatment in combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV…”
Get full text

Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890) by Pfisterer, Jacobus, Joly, Florence, Kristensen, Gunnar, Rau, Joern, Mahner, Sven, Pautier, Patricia, El-Balat, Ahmed, Kurtz, Jean Emmanuel, Canzler, Ulrich, Sehouli, Jalid, Heubner, Martin L., Hartkopf, Andreas D., Baumann, Klaus, Hasenburg, Annette, Hanker, Lars Ch, Belau, Antje, Schmalfeldt, Barbara, Denschlag, Dominik, Park-Simon, Tjoung-Won, Harter, Philipp

“…Abstract only 5501 Background: GOG-0218 established the addition of BEV 15 mg/kg every 3 weeks (q3w) for 15 months to standard front-line chemotherapy for…”
Get full text